2020
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors
Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas 2020, 144: 37-44. PMID: 33358206, PMCID: PMC7773136, DOI: 10.1016/j.maturitas.2020.10.018.Peer-Reviewed Original ResearchConceptsGynecologic cancer survivorsFemale Sexual Functioning IndexVaginal Assessment ScaleCancer survivorsLaser therapyTreatment armsSexual functionFractional COMedian total FSFI scoreMedian UDI-6 scoreRandomized sham-controlled trialUDI-6 scoresUrinary Distress InventorySerious adverse eventsSham-controlled trialProportion of patientsMedian VAS scoreTotal FSFI scoreFractional CO2 laser therapyCO2 laser therapyLaser treatmentPreliminary evidenceAdenocarcinoma histologyUrinary symptomsAdverse events
2019
The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).
Lustberg M, Pfeiffer P, Qvortrup C, Muro K, Bengtson M, Nittve M, Sonesson C, Nagahama F, Sonehara Y, Carlsson C. The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps3616-tps3616. DOI: 10.1200/jco.2019.37.15_suppl.tps3616.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyChronic chemotherapy-induced peripheral neuropathyMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsPlacebo-controlled studyDisease-free survivalOxaliplatin-induced neuropathyTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsThe Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).
Pfeiffer P, Qvortrup C, Muro K, Lustberg M, Nagahama F, Sonehara Y, Bengtson M, Nittve M, Sonesson C, Carlsson C. The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps722-tps722. DOI: 10.1200/jco.2019.37.4_suppl.tps722.Peer-Reviewed Original ResearchMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsOxaliplatin-induced neuropathyDisease-free survivalPatient reported symptomsTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsPeripheral neuropathyTreatment breaks